We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+43.75%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
AUM
$747M
AUM Growth
+$206M
Cap. Flow
+$79.9M
Cap. Flow %
10.7%
Top 10 Hldgs %
63.69%
Holding
56
New
12
Increased
11
Reduced
13
Closed
16
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ATRS
51
DELISTED
Antares Pharma, Inc.
ATRS
-1,336,700
Closed -$4.47M
SBBP
52
DELISTED
Strongbridge Biopharma plc.
SBBP
-2,578,003
Closed -$6.16M
GWPH
53
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
-30,000
Closed -$3.45M
AMAG
54
DELISTED
AMAG Pharmaceuticals
AMAG
-100,000
Closed -$1.16M
WMGI
55
DELISTED
Wright Medical Group Inc
WMGI
-618,500
Closed -$12.8M
AGN
56
DELISTED
Allergan plc
AGN
-96,504
Closed -$16.2M

Similar funds

Broadfin Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Broadfin Capital held 56 positions worth $747M, up 38% from $541M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Broadfin Capital deployed $79.9M of net new capital in Q4 2019, opening 12 new positions and adding to 11 existing holdings. Its largest new stake was STAAR Surgical: 462,118 shares worth $16.3M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 54% a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $13.6M trimmed.

  • Broadfin Capital's largest Q4 2019 buy was STAAR Surgical: 462,118 shares worth $16.3M.
  • Broadfin Capital added most to Alkermes in Q4 2019, an estimated $15.6M increase.
  • Broadfin Capital's biggest Q4 2019 reduction was Iovance Biotherapeutics, cutting an estimated $13.6M.
  • Broadfin Capital fully exited Allergan plc in Q4 2019, selling an estimated $16.2M.
  • Broadfin Capital's ten largest holdings make up 64% of its $747M portfolio in Q4 2019.
  • Broadfin Capital opened 12 new positions and closed 16 in Q4 2019.
  • Broadfin Capital's portfolio value rose 38% quarter-over-quarter to $747M.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.